MYO 101

Drug Profile

MYO 101

Alternative Names: scAAVrh74.tMCK.hSGCB

Latest Information Update: 22 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nationwide Children's Hospital
  • Developer Myonexus Therapeutics; Nationwide Children's Hospital
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Limb girdle muscular dystrophies

Most Recent Events

  • 20 Dec 2017 US FDA approves initiation of a phase I/IIa trial in Limb girdle muscular dystrophies (Myonexus Therapeutics pipeline, December 2017) before December 2017
  • 13 Dec 2017 Myonexus Therapeutics plans a phase I/IIa trial in Limb girdle muscular dystrophies (LGMD2E) in early 2018
  • 19 Oct 2017 Nationwide Children's Hospital has a published patent application with the Patent Coopertaion Treaty for adeno-associated virus vector delivery of β-sarcoglycan for treatment of Muscular dystrophy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top